Swaraj Paul Barooah has written some pieces that are very critical of some of the recent Indian court decisions on pricing of medicines an on intellectual policy. He is no reliable friend of weak Ip protection but this morning on the Spicy IP blog, he uses all of his formidable legal mind to tear apart the complaints of the US company Pfizer, about some of these recent actions. As always it is tightly-written but it is a technical piece and recommended only for readers with a strong interest in compulsory licensing, refusal of patents and other regulatory issues. For those readers, though, it will be compelling